A previous study found that GLP‐1 receptor agonists and other incretin‐based therapies for T2DM patients were associated with a low risk of developing AS, and their vasculoprotective effects were related to vasodilation, the prevention, and development of endothelial dysfunction, lipid homeostasis, and antiproliferative and anti‐inflammatory effects.65 This evidence concerns the gene GLP1R and type 2 diabetes mellitus.